
DNTH Stock Forecast & Price Target
DNTH Analyst Ratings
Bulls say
Dianthus Therapeutics Inc. shows a positive outlook due to its advancements in clinical trials, including the potential progression of Claseprubart to Part B with promising efficacy signals indicated by better-than-expected interim analysis response rates. The company's robust cash position of approximately $514 million at year-end 2025 supports its operational capabilities and growth potential, reflected in an increased valuation target of $55. Additionally, Claseprubart's improved dosing schedule compared to its competitor, riliprubart, could further enhance its market appeal, contributing to a favorable assessment of the company's pipeline and overall stock performance.
Bears say
Dianthus Therapeutics Inc. faces a precarious financial outlook due to the potential inability to secure adequate funding, which could hinder the advancement of its drug development pipeline. The company's reliance on external financing raises concerns about its capacity to sustain operations and invest in the progress of its therapeutic candidates. Additionally, the possibility of unsuccessful interim results could further exacerbate its financial challenges and impact investor confidence.
This aggregate rating is based on analysts' research of Magenta Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
DNTH Analyst Forecast & Price Prediction
Start investing in DNTH
Order type
Buy in
Order amount
Est. shares
0 shares